Who are DOACs: Rivaroxaban, Dabigatran, Apixaban's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Therapeutic Anticoagulation, Pradaxa, Rivaroxaban, Dabigatran, Dabigatran; Rivaroxaban, Rivaroxaban, dabigatran, apixaban, or edoxaban, No OAC.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/doacs-rivaroxaban-dabigatran-apixaban.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

DOACs: Rivaroxaban, Dabigatran, Apixaban — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DOACs: Rivaroxaban, Dabigatran, Apixaban (DOACs: Rivaroxaban, Dabigatran, Apixaban) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Direct oral anticoagulant. Area: Cardiovascular.

phase 2 Direct oral anticoagulant Factor Xa or thrombin Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

DOACs: Rivaroxaban, Dabigatran, Apixaban (DOACs: Rivaroxaban, Dabigatran, Apixaban) — Bayer. Rivaroxaban, dabigatran, and apixaban are direct oral anticoagulants that inhibit Factor Xa or thrombin.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DOACs: Rivaroxaban, Dabigatran, Apixaban TARGET	DOACs: Rivaroxaban, Dabigatran, Apixaban	Bayer	phase 2	Direct oral anticoagulant	Factor Xa or thrombin
Therapeutic Anticoagulation	Therapeutic Anticoagulation	Unity Health Toronto	phase 3	Anticoagulant	Factor Xa or thrombin
Pradaxa	dabigatran etexilate	Generic (originally Boehringer Ingelheim)	marketed	Direct oral anticoagulant (DOAC) — direct thrombin inhibitor	Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Ribosyldihydronicotinamide dehydrogenase [quinone]	2010-10-19
Rivaroxaban, Dabigatran	Rivaroxaban, Dabigatran	University Hospital, Grenoble	marketed	Direct oral anticoagulant (DOAC)	Factor Xa (rivaroxaban); Thrombin/Factor IIa (dabigatran)
Dabigatran; Rivaroxaban	Dabigatran; Rivaroxaban	University Hospital, Grenoble	marketed	Direct oral anticoagulant (DOAC)	Dabigatran: Factor IIa (thrombin); Rivaroxaban: Factor Xa
Rivaroxaban, dabigatran, apixaban, or edoxaban	Rivaroxaban, dabigatran, apixaban, or edoxaban	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	marketed	Direct oral anticoagulant (DOAC)	Factor Xa (rivaroxaban, apixaban, edoxaban) or Thrombin (dabigatran)
No OAC	no-oac	Pfizer	marketed	Direct Oral Anticoagulant	Factor Xa

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Direct oral anticoagulant class)

Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DOACs: Rivaroxaban, Dabigatran, Apixaban — Competitive Intelligence Brief. https://druglandscape.com/ci/doacs-rivaroxaban-dabigatran-apixaban. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab